(3.9-10.0 mmol/L) from 11.7 to 16.8 hours a day with increased scan rate5* (p<0.001)
across patients with T1D and T2D5* (p<0.001)
in patients with T2D2* (p<0.001)
(>10 mmol/L) by 1 hr/day with no significant increase in time spent in hypoglycemia (<3.9 mmol/L)11*†
Explore upcoming virtual and in-person educational events.
SMBG=self-monitoring of blood glucose; T1D=type 1 diabetes; T2D=type 2 diabetes.
* Data from this study were collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system with optional real-time glucose alarms. Therefore, the study data are applicable to both products.
† Results from the SELFY study of diabetes self-management in children (4-12 years) and teenagers (13-17 years). Questionnaire was either completed by children or their caregiver.
1. Bolinder J, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388(10057):2254-63.
2. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73.
3. Ajjan R. Insights from real world use of flash continuous glucose monitoring. Symposium presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, FL.
4. Seibold A, et al. A meta-analysis of real-world observational studies on the impact of flash glucose monitoring on glycemic control as measured by A1C. Poster presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, FL.
5. Lang J, et al. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control [Abstract 089]. Diabetes Technol Ther 2019;21(1):A–40.
6. Kröger J, et al. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. Diabetes Ther 2020;11(1):279-91.
7. Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther 2019;21(2):81-85.
8. Beck RW, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 2019;42(3):400-05.
9. Data on file, Abbott Diabetes Care Inc.
10. Yaron M, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care 2019;42(7):1178-84.
11. Campbell FM, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes 2018;19(7):1294-301.
12. Berard L, Virdi N, Dunn TC. Canadian realworld analysis of flash glucose monitoring and impact on glycemic control. Poster presented at: Diabetes Canada Conference; October 2-5, 2019; Winnipeg, MB.
This site is intended for Healthcare Professionals only. Visit patient site.
The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in adults aged 18 years and older with diabetes mellitus. Always read and follow the label/insert.
The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.
You are now being redirected to a third-party website not under the control of Abbott. Abbott is not responsible for the contents of such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply the endorsement of the linked site by Abbott.
Do you wish to leave this site?